Literature DB >> 23207610

Diabetes and pancreatic cancer.

T Muniraj1, S T Chari.   

Abstract

The relationship between diabetes and pancreatic cancer is complex. Diabetes or impaired glucose tolerance is present in more than 2/3rd of pancreatic cancer patients. Epidemiological studies have consistently shown a modest increase in the risk of pancreatic cancer in type 2 diabetes, with an inverse relationship to duration of disease. Additionally, recent studies suggest that anti-diabetic medications may modulate the risk of pancreatic cancer in type 2 diabetes. Subjects >50 years of age with new onset diabetes are at higher risk of having pancreatic cancer. However, to screen new-onset diabetes for pancreatic cancer, additional markers are needed that can distinguish pancreatic cancer-associated diabetes from type 2 diabetes.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23207610      PMCID： PMC3932318     

Source DB:  PubMed          Journal:  Minerva Gastroenterol Dietol        ISSN： 1121-421X


  89 in total

Review 1.  Proliferative effects of insulin analogues on mammary epithelial cells.

Authors:  Doris Mayer; Ashish Shukla; Harald Enzmann
Journal:  Arch Physiol Biochem       Date:  2008-02       Impact factor: 4.076

2.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

Review 3.  Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer.

Authors:  K S Goonetilleke; A K Siriwardena
Journal:  Eur J Surg Oncol       Date:  2006-11-09       Impact factor: 4.424

Review 4.  Clinical relevance of serological markers in the detection and follow-up of pancreatic adenocarcinoma.

Authors:  R A Audisio; P Veronesi; P Maisonneuve; A Chiappa; B Andreoni; E Bombardieri; J G Geraghty
Journal:  Surg Oncol       Date:  1996-04       Impact factor: 3.279

5.  Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer.

Authors:  Suresh T Chari; Cynthia L Leibson; Kari G Rabe; Lawrence J Timmons; Jeanine Ransom; Mariza de Andrade; Gloria M Petersen
Journal:  Gastroenterology       Date:  2007-10-26       Impact factor: 22.682

6.  Antidiabetic therapies affect risk of pancreatic cancer.

Authors:  Donghui Li; Sai-Ching J Yeung; Manal M Hassan; Marina Konopleva; James L Abbruzzese
Journal:  Gastroenterology       Date:  2009-04-16       Impact factor: 22.682

7.  Glucose tolerance and insulin secretion in pancreatic cancer.

Authors:  L Gullo; D Ancona; R Pezzilli; R Casadei; O Campione
Journal:  Ital J Gastroenterol       Date:  1993 Nov-Dec

8.  Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I.

Authors:  E Liefvendahl; H J Arnqvist
Journal:  Horm Metab Res       Date:  2008-04-07       Impact factor: 2.936

9.  Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis.

Authors:  J Everhart; D Wright
Journal:  JAMA       Date:  1995 May 24-31       Impact factor: 56.272

10.  Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study.

Authors:  J Rosenstock; V Fonseca; J B McGill; M Riddle; J P Hallé; I Hramiak; P Johnston; M Davis
Journal:  Diabetologia       Date:  2009-07-16       Impact factor: 10.122
View more
  22 in total

1.  Metformin Improves Survival in Patients with Pancreatic Ductal Adenocarcinoma and Pre-Existing Diabetes: A Propensity Score Analysis.

Authors:  S Amin; G Mhango; J Lin; A Aronson; J Wisnivesky; P Boffetta; Aimee L Lucas
Journal:  Am J Gastroenterol       Date:  2016-07-19       Impact factor: 10.864

Review 2.  Pancreatic Cancer and Diabetes Mellitus.

Authors:  Ayush Sharma; Suresh T Chari
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12

3.  Analysis of dysregulation of immune system in pancreatic cancer based on gene expression profile.

Authors:  Baosheng Wang; Shaolong Sun; Zhen Liu
Journal:  Mol Biol Rep       Date:  2014-03-12       Impact factor: 2.316

4.  Effects of Metformin and a Mammalian Target of Rapamycin (mTOR) ATP-Competitive Inhibitor on Targeted Metabolomics in Pancreatic Cancer Cell Line.

Authors:  Ghada A Soliman; Sharalyn M Steenson; Asserewou H Etekpo
Journal:  Metabolomics (Los Angel)       Date:  2016-08-20

5.  Epidemiology of Pancreatic and Periampullary Cancer.

Authors:  Prabin Thapa
Journal:  Indian J Surg       Date:  2015-10-17       Impact factor: 0.656

6.  Exploring the relationship between nonalcoholic fatty liver disease and pancreatic cancer by computed tomographic survey.

Authors:  Chao-Feng Chang; Yu-Chen Tseng; Hsin-Hung Huang; Yu-Lueng Shih; Tsai-Yuan Hsieh; Hsuan-Hwai Lin
Journal:  Intern Emerg Med       Date:  2017-12-12       Impact factor: 3.397

Review 7.  The early diagnosis of pancreatic cancer and diabetes: what's the relationship?

Authors:  Changsong Zhang; Guangshun Yang; Yang Ling; Guihua Chen; Tianbao Zhou
Journal:  J Gastrointest Oncol       Date:  2014-12

8.  Pancreatic Cancer-Derived Exosomes Cause Paraneoplastic β-cell Dysfunction.

Authors:  Naureen Javeed; Gunisha Sagar; Shamit K Dutta; Thomas C Smyrk; Julie S Lau; Santanu Bhattacharya; Mark Truty; Gloria M Petersen; Randal J Kaufman; Suresh T Chari; Debabrata Mukhopadhyay
Journal:  Clin Cancer Res       Date:  2014-10-29       Impact factor: 12.531

9.  Long-term patterns of fasting blood glucose levels and pancreatic cancer incidence.

Authors:  NaNa Keum; Kyoung Hwa Ha; Ying Bao; Moon Jae Chung; Hyeon Chang Kim; Edward L Giovannucci
Journal:  Cancer Causes Control       Date:  2017-12-02       Impact factor: 2.506

Review 10.  Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up.

Authors:  Rushika M Perera; Nabeel Bardeesy
Journal:  Cancer Discov       Date:  2015-11-03       Impact factor: 39.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.